Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Cell. 2010 Dec 14;18(6):606-18. doi: 10.1016/j.ccr.2010.10.032.

β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.

Author information

1
Department of Haematological Medicine, King's College London, Denmark Hill, UK.

Abstract

Identification of molecular pathways essential for cancer stem cells is critical for understanding the underlying biology and designing effective cancer therapeutics. Here, we demonstrated that β-catenin was activated during development of MLL leukemic stem cells (LSCs). Suppression of β-catenin reversed LSCs to a pre-LSC-like stage and significantly reduced the growth of human MLL leukemic cells. Conditional deletion of β-catenin completely abolished the oncogenic potential of MLL-transformed cells. In addition, established MLL LSCs that have acquired resistance against GSK3 inhibitors could be resensitized by suppression of β-catenin expression. These results unveil previously unrecognized multifaceted functions of β-catenin in the establishment and drug-resistant properties of MLL stem cells, highlighting it as a potential therapeutic target for an important subset of AMLs.

PMID:
21156284
DOI:
10.1016/j.ccr.2010.10.032
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center